Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5790
-0.0159-2.67%
Pre-market: 0.58990.0109+1.88%07:52 EDT
Volume:2.92M
Turnover:1.71M
Market Cap:160.96M
PE:-1.16
High:0.6000
Open:0.5905
Low:0.5751
Close:0.5949
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.49
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.15
PE(LYR):-2.24

Loading ...

Humacyte Says FDA Authorizes Symvess Shelf Life Extension to 36 Months

Reuters
·
Yesterday

Humacyte - to File Supplemental Bla in Nov 2026 for Dialysis Access Indication

THOMSON REUTERS
·
Yesterday

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

THOMSON REUTERS
·
Yesterday

Humacyte Plans FDA Filing for Acellular Tissue Engineered Vessel in Dialysis Access

MT Newswires Live
·
Aug 24

Humacyte Says Phase 3 V012 Trial Shows ATEV Extends Catheter-Free Dialysis Time in Women

Reuters
·
Aug 24

Humacyte - Seeks to Add Dialysis Access as Second Approved Indication for Atev

THOMSON REUTERS
·
Aug 24

Humacyte - Supplemental Bla to be Supported by Three Phase 3 Studies of Atev

THOMSON REUTERS
·
Aug 24

Humacyte - to File Supplemental Bla with FDA for Atev in Dialysis Access in November 2026

THOMSON REUTERS
·
Aug 24

Humacyte Confirms Plans for Atev Supplemental Bla Filing for Dialysis Access Following FDA Discussions

THOMSON REUTERS
·
Aug 24

Humacyte Director Keith Anthony Jones Reports Purchase of 10,000 Common Shares Worth $6,930

Reuters
·
Aug 22

Humacyte Director Keith Anthony Jones Acquires 30,000 Shares Worth $17,820

Reuters
·
Aug 20

Humacyte Says Phase 3 V007 Trial Results Show ATEV Tops Fistula for Hemodialysis Access at One Year

Reuters
·
Aug 19

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

THOMSON REUTERS
·
Aug 19

Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints

TIPRANKS
·
Aug 14

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Humacyte Falls After Wider-than-Expected Quarterly Loss

Reuters
·
Aug 12

Humacyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Humacyte Q2 Net Loss Widens on Inventory, Production Costs

Reuters
·
Aug 12

Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate

Benzinga Earnings
·
Aug 12

Humacyte Q2 Cash & Investments USD 80.3 Million

THOMSON REUTERS
·
Aug 12